ERBB2 and breast carcinoma: In the phase II Zo-NAnTax trial [17], we assessed the benefit in pCR in HER2-positive breast cancer by adding zoledronic acid (ZOL) to a neoadjuvant treatment regimen based on anthracycline + cyclophosphamide followed docetaxel + trastuzumab.